Canada Markets open in 7 hrs 46 mins

Zai Lab Ltd. (ADRs) (1ZL.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
35.80-1.00 (-2.72%)
At close: 08:19AM CET
Full screen
Previous Close36.80
Bid36.40 x 0
Ask36.80 x 0
Day's Range35.80 - 35.80
52 Week Range21.40 - 51.50
Avg. Volume19
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Zai Lab Announces Participation in February Investor Conferences

    SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in February 2023: Guggenheim Oncology ConferenceFireside Chat: Wednesday, February 8, 2023, 3:20 p.m. ESTLocation: New York SVB Securities Global Biopharma ConferenceFireside Chat: Tuesday, February 14, 2023, 8:00 a.m. EST Citi Biotech C-Suite Fireside Chat SeriesFir

  • GlobeNewswire

    Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA

    SHANGHAI and CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR) for the treatment of infections caused by Acinetobacter baumannii, including multidrug-resistant and carbapenem-resistant (CRAB) strains. “The CDE’s decision to grant pri

  • GlobeNewswire

    Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

    SHANGHAI and CAMBRIDGE, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include both QINLOCK® (ripretinib) for advanced gastrointestinal stromal tumor (GIST) patients who have received prior treatment with three or more kina